Market Price

0.80 

-0.04 -4.8%

as of Oct 18 '19

52 Week Range:

0.77 3.99


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research industries. The company sells its products through its direct sales force; and a network of independent distributors, and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 3.18
3.79
6.66
6.93
7.61
7.59
8.26
8.81
9.11
5.08
3.26
growth rate 19.2% 75.7% 4.1% 9.8% -0.3% 8.8% 6.7% 3.4% -44.2% -35.8%
Earnings BIT -81.67
12.92
61.36
18.20
19.40
10.30
15.44
13.51
8.32
5.48
6.71
growth rate 100.0% 374.9% -70.3% 6.6% -46.9% 49.9% -12.5% -38.4% -34.1% 22.4%
Avg.PE -3.90
7.16
3.16
13.91
17.83
60.98
26.14
12.42
42.71
-1.04
-1.04
growth rate 100.0% -55.9% 340.2% 28.2% 242.0% -57.1% -52.5% 243.9% -100.0% 0.0%
ROA -45.03
9.03
41.20
9.38
9.40
4.55
7.34
7.19
-32.82
-18.20
-12.82
growth rate 100.0% 356.3% -77.2% 0.2% -51.6% 61.3% -2.0% -100.0% 0.0% 0.0%
ROE -76.72
16.28
54.77
10.66
10.81
5.47
9.06
10.61
-62.38
-46.31
-40.44
growth rate 100.0% 236.4% -80.5% 1.4% -49.4% 65.6% 17.1% -100.0% 0.0% 0.0%
ROIC -53.93
11.81
47.35
9.58
9.93
5.02
9.05
8.03
-38.49
-20.78
-13.26
growth rate 100.0% 300.9% -79.8% 3.7% -49.5% 80.3% -11.3% -100.0% 0.0% 0.0%
Cur. Ratio 2.11
2.67
8.27
8.63
8.52
3.66
3.13
8.10
5.28
5.30
4.92
growth rate 26.5% 209.7% 4.4% -1.3% -57.0% -14.5% 158.8% -34.8% 0.4% -7.2%
Quick Ratio 0.92
1.14
6.83
6.20
6.83
2.10
1.39
6.09
3.85
3.62
3.15
growth rate 23.9% 499.1% -9.2% 10.2% -69.3% -33.8% 338.1% -36.8% -6.0% -13.0%
Leverage 1.97
1.67
1.14
1.13
1.17
1.24
1.23
1.70
2.30
2.96
3.44
growth rate -15.2% -31.7% -0.9% 3.5% 6.0% -0.8% 38.2% 35.3% 28.7% 16.2%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 27.40
22.90
11.80
24.09
12.60
19.80
21.48
20.66
20.16
21.29
25.22
growth rate -16.4% -48.5% 104.2% -47.7% 57.1% 8.5% -3.8% -2.4% 5.6% 18.5%
Acct.Payable 13.17
11.80
8.20
9.47
8.33
9.02
8.05
8.12
growth rate -10.4% -30.5% 15.5% -12.1% 8.3% -10.8% 0.9%
Cur.Assets 75.20
68.40
101.30
115.01
110.50
76.70
68.95
163.23
133.49
112.59
86.66
growth rate -9.0% 48.1% 13.5% -3.9% -30.6% -10.1% 136.8% -18.2% -15.7% -23.0%
Total Assets 129.50
132.40
160.90
171.50
197.40
226.50
242.84
363.68
249.59
192.97
151.66
growth rate 2.2% 21.5% 6.6% 15.1% 14.7% 7.2% 49.8% -31.4% -22.7% -21.4%
Cash 5.20
6.10
58.00
71.09
74.90
22.30
9.10
101.95
77.11
23.56
30.28
growth rate 17.3% 850.8% 22.6% 5.4% -70.2% -59.2% 1,020.1% -24.4% -69.4% 28.5%
Inventory 42.30
39.20
17.60
19.84
20.80
29.70
33.52
35.13
32.59
32.81
30.36
growth rate -7.3% -55.1% 12.7% 4.9% 42.8% 12.9% 4.8% -7.2% 0.7% -7.5%
Cur.Liabilities 35.70
25.60
12.30
13.33
13.00
21.00
22.06
20.15
25.28
21.23
17.60
growth rate -28.3% -52.0% 8.4% -2.5% 61.5% 5.0% -8.7% 25.5% -16.0% -17.1%
Liabilities 63.60
53.10
19.60
20.17
28.00
43.50
45.87
149.79
140.87
127.78
107.61
growth rate -16.5% -63.1% 2.9% 38.8% 55.4% 5.4% 226.6% -6.0% -9.3% -15.8%
LT Debt 23.50
19.20
0.10
0.01
0.00
0.00
2.37
91.51
92.23
92.96
81.38
growth rate -18.3% -99.5% -90.0% -100.0% 3,761.4% 0.8% 0.8% -12.5%
Equity 65.90
79.30
141.30
151.33
169.40
183.00
196.97
213.89
108.73
65.20
44.05
growth rate 20.3% 78.2% 7.1% 11.9% 8.0% 7.6% 8.6% -49.2% -40.0% -32.4%
Common Shares 20.00
21.00
22.00
22.00
22.00
23.00
24.00
27.00
28.00
27.00
26.00
growth rate 5.0% 4.8% 0.0% 0.0% 4.6% 4.4% 12.5% 3.7% -3.6% -3.7%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 2.90
2.20
2.80
2.44
3.00
4.49
8.27
7.09
4.22
4.84
7.53
growth rate -24.1% 27.3% -13.0% 23.2% 49.6% 84.2% -14.2% -40.6% 14.8% 55.6%
Cash Dividends 0.00
0.00
0.00
2.15
3.20
4.40
5.03
5.10
0.00
growth rate 49.2% 37.5% 14.3% 1.4% -100.0%
Cash From OA 10.70
14.70
23.10
20.46
20.00
9.40
16.06
13.16
10.23
9.25
7.23
growth rate 37.4% 57.1% -11.5% -2.2% -53.0% 70.8% -18.1% -22.3% -9.6% -21.9%
FCF per Share -0.39
0.20
0.65
0.67
0.21
-0.28
-0.69
-0.52
-0.46
-0.25
-0.38
growth rate 100.0% 225.0% 3.1% -68.7% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock -4.94
-5.30
0.00
3.64
2.94
0.86
-7.80
growth rate 0.0% 0.0% -19.2% -70.9% -100.0%
FCF -2.00
4.00
14.00
11.00
5.00
-14.00
-12.00
-15.00
-12.00
-7.00
-10.00
growth rate 100.0% 250.0% -21.4% -54.6% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 140.10
125.90
89.60
77.95
82.50
91.20
104.87
100.20
99.61
99.14
97.04
growth rate -10.1% -28.8% -13.0% 5.8% 10.6% 15.0% -4.5% -0.6% -0.5% -2.1%
Op.Income -79.60
13.70
60.50
15.59
17.30
9.60
15.44
13.51
8.32
5.48
6.71
growth rate 100.0% 341.6% -74.2% 11.0% -44.5% 60.8% -12.5% -38.4% -34.1% 22.4%
IBT -81.70
12.90
61.40
18.20
19.40
10.20
15.40
22.94
-42.14
-39.88
-23.18
growth rate 100.0% 376.0% -70.4% 6.6% -47.4% 51.0% 49.0% -100.0% 0.0% 0.0%
Net Income -77.80
11.80
60.40
15.59
17.30
9.60
17.21
21.80
-100.63
-40.27
-22.09
growth rate 100.0% 411.9% -74.2% 11.0% -44.5% 79.3% 26.6% -100.0% 0.0% 0.0%
EPS -3.84
0.56
2.80
0.72
0.76
0.40
0.72
0.48
-4.40
-1.88
-1.04
growth rate 100.0% 400.0% -74.3% 5.6% -47.4% 80.0% -33.3% -100.0% 0.0% 0.0%
Gross Profit 62.50
57.00
43.90
40.13
45.10
45.20
49.38
46.51
43.48
41.89
41.45
growth rate -8.8% -23.0% -8.6% 12.4% 0.2% 9.2% -5.8% -6.5% -3.7% -1.1%
R&D 7.50
7.30
4.60
3.21
3.10
3.70
4.29
5.07
5.04
5.66
5.37
growth rate -2.7% -37.0% -30.3% -3.3% 19.4% 16.0% 18.1% -0.6% 12.2% -5.1%

Quarterly Statements

Item Name Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Earnings BIT 1.73
1.24
1.92
1.32
1.21
growth rate -28.4% 55.1% -31.1% -8.7%
Balance Sheet Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Acct.Receivable 24.43
24.91
25.22
24.78
25.52
growth rate 2.0% 1.2% -1.8% 3.0%
Acct.Payable 20.49
20.68
8.12
19.64
18.47
growth rate 0.9% -60.8% 142.0% -5.9%
Cur.Assets 108.67
93.48
86.66
85.15
82.00
growth rate -14.0% -7.3% -1.7% -3.7%
Total Assets 194.45
183.33
151.66
172.65
171.70
growth rate -5.7% -17.3% 13.8% -0.6%
Cash 49.43
35.68
30.28
29.43
24.99
growth rate -27.8% -15.1% -2.8% -15.1%
Inventory 34.82
32.89
30.36
30.94
31.49
growth rate -5.5% -7.7% 1.9% 1.8%
Cur.Liabilities 20.80
20.87
17.60
19.81
24.41
growth rate 0.3% -15.6% 12.6% 23.2%
Liabilities 127.76
115.24
107.61
128.48
132.63
growth rate -9.8% -6.6% 19.4% 3.2%
LT Debt 95.18
82.05
81.38
81.94
81.79
growth rate -13.8% -0.8% 0.7% -0.2%
Equity 66.69
68.08
44.05
44.17
39.07
growth rate 2.1% -35.3% 0.3% -11.5%
Common Shares 1.22
1.22
1.21
1.21
1.21
growth rate 0.0% -0.9% 0.0% 0.0%
Cash Flow Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Capital Expenditures 3.88
4.31
5.04
3.11
3.08
growth rate 11.1% 17.0% -38.2% -1.1%
Cash Dividends
growth rate
Cash From OA 1.74
2.93
0.23
2.68
1.53
growth rate 68.8% -92.2% 1,070.3% -43.1%
Sale Purchase of Stock
growth rate
FCF -2.14
-1.38
-4.81
-0.43
-1.55
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Sales 25.00
23.71
24.52
22.03
22.50
growth rate -5.2% 3.4% -10.2% 2.1%
Op.Income 1.73
1.24
1.92
1.32
1.21
growth rate -28.4% 55.1% -31.1% -8.7%
IBT 0.75
0.97
-23.69
-0.11
0.25
growth rate 29.3% -100.0% 0.0% 100.0%
Net Income 0.59
0.90
-23.96
-0.21
-5.41
growth rate 50.8% -100.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 10.81
9.98
10.23
9.34
9.44
growth rate -7.7% 2.5% -8.8% 1.1%
R&D 1.42
1.29
1.39
1.31
1.45
growth rate -9.0% 7.3% -5.4% 10.5%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (0.00)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -1.04 -0.58 3.17
EPS / Growth -20.4% -1.37 15.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 1.0% 1.0%
Future PE 0.01 1.73 1.73
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.